

Pharmaceutical Firm, ARTEC, Inc., Announces Testing Launch of TUBERCIN(TM) -- Mission Focus is on the Testing of HIV/AIDS & Tuberculosis Patients in South Africa

Monday September 24, 7:01 am ET

OKLAHOMA CITY--(BUSINESS WIRE)--ARTEC, Inc., (Pink Sheets: ATKJ - News), visionary pharmaceutical firm, has acquired the preliminary outline to be used for the testing protocol from a sponsoring scientific group in South Africa for TUBERCIN(TM), a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant.

"We are grateful to further test the medicinal impact of TUBERCIN(TM) in South Africa on their suffering patients," said Mr. Gerry Knight, Executive Vice-President of ARTEC, Inc. "Their dedicated partnership is enabling the launch testing of an immunostimulant we believe will greatly impact the devastation of HIV/AIDS, Tuberculosis and cancer worldwide. The continued assistance from our shareholders will also uphold our commitment to speedily developing TUBERCIN(TM) as a treatment that could soon bring hope to the millions suffering."

Early in October 2006, Dr. Ronald Shinn, President and Board of Directors Chairman of ARTEC, Inc. arrived in South Africa at the invitation of a group of prominent business and professional South Africans. Although previous in depth communications had occurred, the trip enabled both sides the face-to-face opportunity to explore the use of TUBERCIN(TM) on the devastating impact of HIV/AIDS in Africa. The problem of AIDS is horrendous especially when witnessing it first hand.

The Desperate Need for Relief of HIV/AIDS and Tuberculosis in South Africa is currently experiencing one of the most severe HIV/AIDS epidemics in the world. As reported by the World Health Organization, HIV and Tuberculosis form a lethal combination each speeding the other's progress. By the end of 2005, there were five and a half million people living with HIV in South Africa, and almost 1,000 AIDS deaths occurring every day.

The Company, together with the cooperation of Mr. Rodney Watson, Director of ARTEC, Inc. South Africa, has assembled a team of scientific personnel necessary for the South Africa FDA project. Emerging as the chief scientist for ARTEC, Inc. is Dr. Shawn Pruitt from the U.S.A. Dr. Pruitt and his colleagues have been working diligently in the development of information and materials on research needed for this project.

Recently, ARTEC, Inc. received the preliminary outline of the Testing Protocol to be used from the sponsoring scientific group in South Africa. It is advocating the testing of TUBERCIN(TM) on human patients in the hospital afflicted with AIDS and Tuberculosis. The testing will begin with under 100 patients. ARTEC, Inc. is

working on this project as high priority and will provide more information as it becomes known.

In addition to working on the FDA project, Artec, Inc. has initiated direct contact with JSE Limited, formerly the Johannesburg Securities Exchange, and is in the process of establishing membership.

President Dr. Ronald Shinn has made a commitment, on behalf of ARTEC, Inc. to raise the necessary funding to combat HIV/AIDS in Africa and world wide. The Company appreciates the continued shareholders support!

ARTEC, Inc. intends to release further information on the progress of its product developments and integration. For more information on ARTEC, Inc., visit www.artec-inc.net.

Forward Looking Statements

The Company cautions the investors that forward-looking statements in this press release involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the Company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect the Company's expectation with regard to these forward-looking statements or the occurrence of unanticipated events.

Contact:
ARTEC, Inc.
Gerry Knight, 405-949-1808
www.ARTEC-Inc.net

Source: ARTEC, Inc.